The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine

“…Direct comparisons of venlafaxine and paroxetine appeared to favor venlafaxine (Poirier and Boyer, 1999;Ballus et al, 2000). However, as has been pointed out elsewhere (Nemeroff et al, 2008), in these studies low doses of paroxetine were often compared to high doses of venlafaxine, and serum paroxetine concentrations were not reported when doses of 30-40 mg/day were used.…”

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis

“…Therefore, in our analysis, only the response rate data of this study was considered. Furthermore, in two studies included only in Smith et al (2002), a fair number of patients with dysthymia (Ballus et al 2000) or patients with a bipolar disorder (Zanardi et al 2000) participated, thus limiting the relevance for major depression. With one exception (Zanardi et al 2000), the ORs for remission in studies included by Smith et al (2002), but excluded from our analysis, were above 1.40.…”

NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test

“…Paroxetine hydrochloride is one of the most potent inhibitors of the reuptake of serotonin (5-hydroxytryptamine ) of all the currently available antidepressants including the class of SSRIs with currently approved indications for the treatment of depression, obsessive-compulsive disorder, panic disorder, and social anxiety (Anderson 2000;Ballus et al 2000;Bourin et al 2001;Chaudhry et al 2002;Claghorn et al 1992;Emslie et al 2006;Danish University Antidepressant Group 1990;Keller et al 2001;Nemeroff 1993;Rapaport et al 2003;Yonkers et al 2008). It is also used in the treatment of generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and chronic headache .…”